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APLIKASI LC-MS-MS UNTUK MENGKAJI KESAN-KESAN BERPUASA, 
MAKANAN DAN ANTASID  TERHADAP FARMAKOKINETIK SIMVASTATIN  
PADA SUKARELAWAN MALAYSIA YANG SIHAT 
 
 
 
ABSTRAK 
 
 
Simvastatin ialah sejenis analog lovastatin dalam bentuk lakton yang 
digunakan untuk merawat hipekolestrolemia. Simvastatin menurunkan paras 
plasma kolestrol dengan merencat 3-hidroksi-3-metilglataril-CoA reduktase. 
Matlamat kajian ini adalah untuk membangun dan mengesahkan kaedah 
analisis yang cukup sensitif bagi mengukur simvastatin dalam plasma dan 
seterusnya diikuti dengan kajian farmakokinetik komparatif dos tunggal oral 40 
mg simvastatin dalam keadaan berpuasa, kehadiran makanan dan keadaan 
diberi antasid. 
Kesemua kaedah yang dibangun adalah menggunakan teknik HPLC 
dengan berbagai kaedah pengesanan (1) Kromatografi cecair-ultra lembayung 
(HPLC-UV); pengesahan kaedah HPLC-UV memberikan ketelitian dan 
ketepatan < 9%. Lineariti berjulat 20-1000 ng/mL dan had pengukuran dan had 
kuantifikasi adalah 15 ng/mL dan 20 ng/mL dicapai. (2) Kromotografi cecair-
spektrometri jisim (LC-MS); pengesahan kaedah LC-MS memberikan ketelitian 
dan ketepatan < 10%. Lineariti  berjulat 0.5-20 ng/mL  dengan had pengukuran 
0.4 ng/mL  dan had  kuantifikasi 0.5 ng/mL dicapai. (3) Kromatografi cecair-
spektrometri jisim tandem (LC-MS-MS). Pengesahan kaedah LC-MS-MS 
memberikan ketelitian dan ketepatan < 14%. Lineariti berjulat  0.25-50 ng/mL 
dengan had  pengukuran 0.125 ng/mL dan had kuantifikasi 0.25 ng/mL dicapai. 
Kaedah HPLC-UV tidak sensitif bagi mengukur simvastatin dalam 
plasma selepas pengambilan secara oral. Kaedah LC-MS-MS memberikan 
 xx
kespesifikan dan sensitiviti yang lebih berbanding teknik LC-MS, seterusnya 
digunakan untuk menganalisis sampel plasma. 
9 orang sukarelawan lelaki Malaysia yang sihat, berumur antara 22-49 
tahun telah dipilih secara rawak, untuk rekabentuk kajian keratan lintang 3 
kumpulan dalam 3 blok bagi kajian farmakokinetik perbandingan simvastatin. 
Kumpulan pertama subjek yang berpuasa diberikan dos 40 mg simvastatin. 
Kumpulan kedua subjek diberikan dos 40 mg simvastatin beserta antasid (100 
mL). Kumpulan ketiga subjek diberikan makanan tempatan terlebih dahulu 
sebelum mereka diberi dos 40 mg simvastatin. Masa penyahan ialah selama 
seminggu. 
Makanan dan antasid menghasilkan nilai AUC0-24, Cmax dan Tmax yang 
lebih tinggi bagi simvastatin berbanding dengan subjek yang berpuasa. Namun 
nilai Ke dan Vd tidak menunjukkan sebarang perbezaan yang ketara diantara 
subjek yang berpuasa dengan subjek yang mengambil makanan dan subjek 
yang diberikan antasid. Nilai t1/2, untuk subjek yang mengambil makanan 
adalah lebih singkat daripada yang diberi antasid dan berpuasa. Nilai CI adalah 
rendah sedikit dalam keadaan berantasid berbanding dengan keadaan 
berpuasa. Kehadiran makanan dan antasid mempunyai kesan yang sama dan 
tidak menunjukkan perbezaan yang signifikan keatas nilai AUC0-24, Cmax, Ke, 
Tmax, CI dan Vd simvastatin. Penyingkiran simvastatin tidak dipengaruhi oleh 
keadaan berpuasa, makanan dan antasid. Keputusan mencadangkan makanan 
dan antasid meningkatkan biokeperolehan simvastatin dengan meninggikan pH 
salur pencernaan yang seterusnya meningkatkan kestabilan lakton simvastatin 
dan juga pelarutan simvastatin dengan meningkatkan masa pendudukan 
 xxi
gastrik. Keputusan kajian ini mencadangkan bahawa biokeperolehan 
simvastatin adalah bergantung kepada pH. 
 
 xxii
THE APPLICATION OF LC-MS-MS TO STUDY THE EFFECTS OF FASTING, 
FOOD AND ANTACID ON THE PHARMACOKINETICS OF SIMVASTATIN IN 
HEALTHY MALAYSIAN SUBJECTS 
 
 
 
ABSTRACT 
 
Simvastatin a lactone analog of lovastatin which is used in the treatment 
of hypercholesterolemia. Simvastatin lowers plasma cholesterol by inhibiting 3-
hydroxy-3-methylglutaryl-CoA reductase.  
The aims of this study were to develop and validate sufficiently sensitive 
analytical methods for the determination of simvastatin in plasma. This was 
followed by a comparative pharmacokinetic study of a single oral dose of 40 mg 
simvastatin under fasting, food and antacid conditions. 
The assays are HPLC methods with various detection methods: (1) High 
performance liquid chromatography-ultraviolet (HPLC-UV); validation of the 
HPLC-UV revealed precision and accuracy < 9%. Linearity was ranged from 20-
1000 ng/mL with limit of detection of 15 ng/mL and the limit of quantification of 
20 ng/mL was achieved. (2) Liquid chromatography mass spectrometry (LC-
MS); validation of the LC-MS revealed precision and accuracy < 10%. Linearity 
was ranged from 0.5-20 ng/mL with limit of detection of 0.4 ng/mL and the limit 
of quantification of 0.5 ng/mL was achieved. (3) Liquid chromatography tandem 
mass spectrometry (LC-MS-MS); validation of the LC-MS-MS revealed 
precision and accuracy < 14%. Linearity was linear range from 0.25-50 ng/mL 
with limit of detection of 0.125 ng/mL and the limit of quantification of 0.25 
ng/mL was achieved. 
The HPLC-UV was not sensitive in measuring simvastatin in plasma after 
oral dosing. The LC-MS-MS method showed better specificity and sensitivity 
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than the LC-MS technique. Thus LC-MS-MS was used for the analysis of 
plasma samples.  
A randomized study of 9 Malaysian healthy male volunteers aged 22-49 
years old, on 3 groups crossover design in three blocks of 3 subjects was used 
for a comparative pharmacokinetic study of simvastatin. In first group, the 
fasting volunteers were given a single dose of 40 mg tablet of simvastatin. In 
the second group, the volunteers were given 40 mg tablet of simvastatin with 
liquid antacid (100 mL). In the third group, the volunteers were given local food 
before the administration of 40 mg simvastatin. The wash-out period between 
groups was one week.  
Food and antacid produced higher AUC0-24, Cmax and Tmax values of 
simvastatin as compared with fasting condition. The Ke, and Vd did not show 
any significant difference between fasting, food and antacid conditions. The t1/2 
was slightly shorter in food than antacid and fasting conditions. Cl was slightly 
lower in antacid than fasting conditions. Food and antacid have same effect and 
did not show any significant difference on AUC0-24, Cmax, Ke, Tmax, Cl and Vd on 
simvastatin. The results showed that the food and antacid increased the 
bioavailability of simvastatin by increasing the pH of gastrointestinal tract. 
Consequently, that may be lead to increase the stability of lactone form of 
simvastatin as well as improve the dissolution of the simvastatin by increasing 
the gastric residence time. It was concluded that simvastatin bioavailability is pH 
dependent.  
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CHAPTER 1 
INTRODUCTION 
 
Many factors have been found to influence the rate and extent of 
absorption and hence the time course of a drug in the plasma and therefore at 
its site(s) of action. These include the food eaten by the patient, the effect of the 
disease state on drug absorption, the age of the patient, the site(s) of 
absorption of the administered drug, the co-administration of other drugs, the 
physical and chemical properties of the administered drug, the type of dosage 
form, the composition and method of manufacture of the dosage form, the size 
of the dose and the frequency of administration (Welling, 1977; Niazi, 1979; 
Welling, 1989; Gibaldi, 1991; Fleisher et al., 1999; Singh, 1999; Ashford, 
2002a).  
Variability in the bioavailability exhibited by a given drug from different 
formulations of the same type of dosage form, or from different types of dosage 
forms, or by different routes of administration, can cause the plasma 
concentration of the drug to be too high and therefore causes side effects, or it 
may be too low and therefore the drug will be ineffective (Fleisher et al., 1999; 
Ashford, 2002c). 
When a drug is given intravenously it is administered directly into the 
blood and therefore we can be sure that the entire drug reaches the systemic 
circulation. The drugs are therefore said to be 100% bioavailable. However, if a 
drug is given by another route there is no guarantee that the whole dose will 
reach the systemic circulation intact. The fraction of an administered dose of the 
drug that reaches the systemic circulation in the unchanged form is known as 
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the bioavailable dose. The relative amount of an administered dose of a 
particular drug that reaches the systemic circulation intact and the rate at which 
this occurs is known as the bioavailability (Singh, 1999).  
Bioavailability is pharmacokinetic term that describes the rate and extent 
to which the active drug ingredient is absorbed from product and becomes 
available at the site of drug action. The definition would not be valid in the case 
of prodrugs, whose therapeutic action normally depends on their conversion 
into a therapeutically active form prior to or on reaching the systemic circulation. 
It should also be noted that, in the context of bioavailability, the term systemic 
circulation refers primarily to venous blood (excluding the hepatic portal vein, 
which carries blood from the gastrointestinal tract to the liver in the absorption 
phase) and the arterial blood, which carries the intact blood to tissues. 
Therefore, for a drug which is administered orally to be 100% bioavailable, the 
entire dose must move from the dosage form to the systemic circulation. 
However, the drug must be completely released from the dosage form, fully 
dissolved in the gastrointestinal fluids, stable in the solution of the 
gastrointestinal fluids, pass through the gastrointestinal barrier into mesenteric 
circulation without being metabolized and pass through the liver into the 
systemic circulation unchanged (Gibaldi,1991; Wilkinson, 1997; Ashford, 
2002b).  
Anything which adversely affects either the release of the drug from the 
dosage form, its dissolution into the gastrointestinal fluids, its permeation 
through and stability in the gastrointestinal barrier or its stability in the hepatic 
portal circulation will influence the bioavailability of that drug from the dosage 
form in which it is administered (Niazi, 1979; Gibaldi, 1991; Ashford, 2002a) 
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1.1 Background of the Study     
1.1.1 The Effect of Drug Stability in Gastrointestinal Fluids on 
Bioavailability  
Gastrointestinal (GI) fluid pH, which varies considerably along the length 
of the gastrointestinal tract, may have an important influence on drug 
absorption. A drug dosage form is initially exposed to the acidic pH in normal 
stomach (pH 1-3) and an abrupt increase in pH once it enters the small intestine 
as a result of pancreatic secretion. The pH of intestinal fluid ranges from 5-6 in 
the duodenum to 7-8 in the proximal jejunum and approaches a pH of about 8 in 
the large intestine. Among the factors affecting the pH of GI fluid are food 
ingestion, type of diet, stress, general health of the subject and the presence of 
local disease conditions along the tract (Mayersohn, 1979). 
Drug stability in the GI fluids may also play a role in the efficiency of 
absorption of a given dose of a therapeutic agent. Drugs must remain 
sufficiently stable, not only during storage, but also in the gastrointestinal fluids, 
since reactions which result in a product that is pharmacologically inactive or 
less active will reduce biological availability and therapeutic effectiveness. 
Generally, the most important reactions that drugs undergo in the 
gastrointestinal tract are acid and enzymatic hydrolysis (Niazi, 1979; Gibaldi, 
1991; Amidon et al., 1995). 
Hydrolysis in the acidic gastric fluids frequently results in degradation of 
a drug to inactive compounds. Penicillin G is an example of a drug which is 
inactivated by hydrolysis in the stomach (Gibaldi, 1984). The stability of 
penicillin G in gastric fluids can be estimated from kinetic studies in vitro (Poole, 
1979). The half-life of this antibiotic at pH 1 is less than 1 min, while this value is 
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about 9 min at pH 2. The newer semisynthetic penicillin’s are much more 
resistant to acid hydrolysis. For instance, ampicillin has a half-life of several 
hours at pH 1. This improved acid stability is partially responsible for the greater 
efficiency of absorption observed with these agents. Enteric coatings, properly 
formulated, can prevent exposure of a drug to gastric pH and enzymes and may 
minimize its degradation (Gibaldi, 1991; Ashford, 2002b). However, in the case 
of penicillin G, the use of enteric coatings have not been successful because of 
the intrinsically poor absorption of this antibiotic beyond the duodenum, and 
protective coatings generally further decrease its already relatively poor 
availability (Hou and Poole, 1969).  
Stability studies in vitro can predict inefficacy of drugs due to acid 
hydrolysis. An example of such a study was reported for the muscle relaxant P-
chlorobenzaldoxime (Garrett, 1962 cited by Poole, 1979). Although this 
compound is active parenterally, it is ineffective when administered orally. 
Kinetic stability studies in vitro demonstrated a half life of less than 20 min in the 
stomach and the hydrolysis product was not absorbed, accounting for its oral 
ineffectiveness. 
For many compounds which are unstable in acidic gastric fluids, rapid 
dissolution can often result in decreased bioavailability (Gibaldi, 1984). 
Erythromycin and its esters are very unstable in gastric fluid (Rutland et al., 
1979; Reynolds, 1993; Drabant et al., 2004). Studies on a series of 
erythromycin esters showed that bioavailability of these compounds are 
inversely proportional to their dissolution rates in 0.1 N hydrochloric acid.   
In some instances, ester hydrolysis in the GIT is a prerequisite for the 
absorption of a parent drug (Williams, 1985). The stearate and palmitate esters 
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of chloramphenicol are often used, since their low solubility facilitates the 
flavouring of paediatric suspensions (Aguiar et al., 1967). However, the ester 
must be hydrolyzed in the GIT before its absorption and the hydrolysis rate of 
these esters is dependent on their rate of dissolution. Rate of hydrolysis can 
vary by a factor of 100 times when fine particles and large particles of 
chloramphenicol palmitate are compared (Aguiar et al., 1967).   
As some drugs exhibit a chemical stability which is pH dependent, the 
extent of absorption will depend on their time of exposure to GI fluids will in 
effect represent a reduction in administered dose (Poole, 1979; Gibaldi, 1991). 
Drugs such as penicillin G and erythromycin are unstable at the low pH 
of gastric fluid. Since the rate and extent of drug degradation will depend on the 
concentration of drug in solution, an attempt is often made to prepare chemical 
derivatives of those compounds that exhibit a limited solubility at the pH where 
degradation is seen (Mayersohn, 1979). 
The mechanism of ester hydrolysis reaction has been extensively studied 
and can be applied to the hydrolysis of the lactone form (Kaufman, 1990). This 
mechanism involves rate determining nucleophilic attack on a protonated 
lactone to form an intermediate which breaks down to product. Structural 
features which may influence the rate of nucleophilic attack include steric and 
inductive effects. 
Simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase, is administered in the form of lactone prodrug. The lactone ring is 
hydrolyzed in vivo to produce the hydroxyl acid derivatives which are the 
pharmacologically active forms of this drug, and this is believed to take place 
  6
predominantly in the liver (Todd and Goa, 1990; Mauro, 1993; Plosker and 
McTavish, 1995).  
Since lactone hydrolysis reactions are strongly accelerated by general 
acid catalysis, (Serajuddin et al., 1991) it is anticipated that conversion of 
lactone into its hydroxyl acid may occur in the strongly acidic gastric 
environment. Obviously, the desirable tissue selectivity of the lactone form is 
not realized if hydrolytic conversion in the GIT occurs rapidly relative to lactone 
absorption. In addition, in vitro study showed that the lactone form in aqueous 
solution is susceptible to pH dependent hydrolysis at pH 2 (Kaufman, 1990). 
The maximum stability of lactone form is at pH 5 and no degradation of the 
lactone in 24 hours at pH 5 was observed (Serajuddin et al., 1991). Thus, the 
study presented herein is to determine the rate and extent of simvastatin 
lactone form prodrug absorption under the changed pH of stomach fluids in 
fasting condition to non-fasting by food and liquid antacid. 
 
1.1.2 High Performance Liquid Chromatography (HPLC) Assay of the 
Simvastatin in Plasma     
Generally, bioavailability, pharmacokinetics, pharmacokinetic interaction 
and bioequivalence studies require very accurate and precise assay methods 
that are well validated to quantify drugs in biological samples (Poon, 1997). The 
assay methods also have to be very selective to ensure reliable data, free from 
interference of endogenous compounds and possible metabolites in biological 
samples (Shah et al., 2000). The assay methods have to be sensitive enough to 
determine the biological sample concentration of the drug and/or its metabolites 
for a period about five elimination half-life after dosage of the drug. In addition, 
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methods have to be as robust and cost effective as possible, making of 
particular importance to pharmacokinetic studies.  
In addition, the selectivity of any bioanalytical method is greatly affected 
by both the initial clean up sample procedures as well as the subsequent 
analytical process. However, a sufficiently clean sample from plasma is often 
fraught with difficulties because of the presence of interfering and endogenous 
substances. Therefore, sample clean up is the critical step in the overall 
analytical process. Thus method should be short and as simple as possible 
without compromising on the selectivity and sensitivity of the assay. 
In general, solid phase extraction and liquid-liquid extraction are the two 
principle methods used for sample pre-treatment from plasma. Liquid-liquid 
extraction involves the selection of a drug from neutralized aqueous layer into a 
suitable organic solvent such as ethyl acetate and hexane followed by organic 
phase evaporation and residue reconstitution. The extraction procedure of 
liquid-liquid is simpler and less expensive than solid phase extraction. Solid 
phase is based on the principle of modern liquid chromatography (McDowall, 
1989). This operation and clean up procedure prior to analysis seems to be 
complicated and expensive for routine measurements in the clinical laboratory. 
Consequently, a selection of suitable extraction procedure, which is time 
economical, gives the highest possible recovery without interference at the 
elution time of the analyte of interest. Another important point is that the tests 
performed at the stage of method development should be done with the same 
equipment that will actually be used for subsequent routine analysis. 
The criteria considered in typical method development and establishment 
for bioanalytical method includes determination of selectivity, accuracy, 
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precision, recovery, calibration curve, LOQ, LOD and stability (Green, 1996). 
For a method to be considered valid, specific acceptance criteria should be set 
in advance and achieved for accuracy and precision for validation of quality 
control sample (Canson, 1997). 
In addition, the chromatographic methods are more widely accessible 
and capable of being implemented in clinical laboratories with standard high 
performance liquid chromatography (HPLC) instrumentation. Most HPLC 
methods use C18 silica gel reversed phase HPLC columns with isocratic elution 
and an acidic buffer mobile phase.        
Recently, numerous methods for analysis of simvastatin and its 
metabolites determination by HPLC methods with difference detectors 
(ultraviolet, fluorescence and mass spectrometry) have been published (Stubbs 
et al., 1986; Carlucci et al., 1992; Ochiai et al., 1997; Wu et al., 1997; Jemal et 
al., 2000; Wang and Asgharnejad, 2000; Miao and Metcalfe, 2003; Yang et al. 
2003; Yang et al. 2005; Barrett et al., 2006; Pasha et al., 2006). In addition, 
some methods of gas chromatography with mass spectrometry for 
determination of simvastatin and its metabolites have also been published 
(Takano et al., 1990; Morris et al., 1993). However, most of these methods are 
tedious and time consuming, which also considered costly for routine analysis 
work. 
In this study a chromatographic methods will be developed and validated 
based on liquid-liquid extraction. This method will be used for quantitation of 
simvastatin in plasma samples for the pharmacokinetic studies.  
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1.1.3 Justification of the Study 
To the best of the researcher’s knowledge, there is no study available to 
investigate the mechanism of simvastatin absorption with food and liquid 
antacid in healthy younger volunteers. One study has been conducted by 
(Schaefer et al., 2004). This study is not significant enough to confirm the 
pharmacokinetic of simvastatin in fasting and non-fasting. In addition, the study 
was done in elderly patients (mean age 62) with coronary heart disease, while 
the results showed higher effect in taken simvastatin with food than in fasting 
condition. Others studies have been published shown the drugs interactions 
with simvastatin (Gruer et al., 1999; Jacobson, 2004), bioequivalence (Najib et 
al., 2003), grapefruit juice interaction with simvastatin (Lilja et al., 1998; Lilja et 
al., 2000) and pharmacokinetic of simvastatin (Todd and Goa, 1990; Mauro, 
1993; Plosker and McTavish, 1995). 
Given the above, the current study aims to investigate the effect of local 
food (Malaysian food) and liquid antacid on the pharmacokinetic profiles of 
simvastatin in healthy Malaysian volunteers with enough randomization to 
obtain significant findings. In addition, the study will also investigate the stability 
of lactone form by increasing the gastrointestinal fluid pH with local food and 
liquid antacid. As well as to compare the absorption of lactone form enters the 
general circulation when simvastatin is taken together with local food and liquid 
antacid than when simvastatin is taken in the fasting state. Therefore, the 
present study is considered original and has not been carried out and reported 
in Malaysia and elsewhere. 
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1.2 Aims of the Present Study 
In this study, the work was conducted to study the rate and extent of 
absorption of current dosage of 40 mg of simvastatin by neutralizing gastric 
contents and elevating pH of gastric contents by Malaysian food ingredient (fat, 
carbohydrate and protein) and liquid antacid. The aims of this study were: 
1. To develop and validate a sufficiently sensitive analytical method for the 
determination of simvastatin quantities in biological fluids. 
2. To compare the rate and extent of absorption of single oral dose of 40 
mg simvastatin (Zocor®, MSD) as follows. 
Group I.  To study the effect of fasting state on the pharmacokinetic of single 
dose of 40 mg simvastatin in healthy adult male Malaysian volunteers.  
Group II. To study the effect of multi-dose suspension of magnesium and 
aluminium hydroxide mixture on the pharmacokinetic of single dose of 40 mg 
simvastatin in healthy adult male Malaysian volunteers. 
Group III. To study the effect of local food on the pharmacokinetic of single dose 
40 mg simvastatin in healthy adult male Malaysian volunteers.  
                                                                                                                                              
1.3 Contribution of the Study 
The contribution of this study will be reflected in many aspects which 
have the potential to be a useful tool to gain many benefits in the pharmacy 
practice on the impact of research finding on the simvastatin administration and 
uses. In addition, it might provide benefits to the scientific knowledge as it 
contributes to know the stability of lactone form (simvastatin) with food and 
liquid antacid. Furthermore, the output findings from these works will effectively 
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lead to build up strong bases of knowledge for researches on lactone form 
(simvastatin) absorption in future.  
 
1.4 Organization of the Study 
Chapter 1: Background, justification, objectives, contribution and organization 
of study. 
Chapter 2: Literature review of the study. 
Chapter 3: Analytical method for measuring simvastatin in human plasma by 
high performance liquid chromatography (HPLC-UV). 
Chapter 4: Methods validation for measuring simvastatin in human plasma 
using liquid chromatography mass spectrometry (LC-MS) and liquid 
chromatography tandem mass spectrometry (LC-MS-MS).  
Chapter 5: Clinical pharmacokinetic study of simvastatin. 
Chapter 6: General conclusion and recommendation.   
CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Introduction 
This chapter gives an overview of the key concepts of the study. It deals 
with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Then it deals 
with simvastatin one of the major four most important drugs used today to treat 
hyperlipidaemia. Then the chapter goes on to review of pharmacokinetic and 
metabolism. It touches upon lipophilicities, solubilities and partition coefficient of 
HMG-CoA reductase inhibitors, pravastatin, lovastatin, mevastatin and 
simvastatin. The chapter touches upon lactone hydrolysis of HMG-CoA 
reductase inhibitors (lovastatin and simvastatin). The chapter touches briefly on 
the effects of food and pH on drug absorption. Finally, determination of 
simvastatin in human plasma by using HPLC methods concludes the chapter.  
   
2.2 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors 
2.2.1 Chemical Structures 
Mevastatin, the first representative of this new class of statin compounds, 
is derived from a strain of Penicillin citrinum. Lovastatin is a natural product, 
simvastatin and pravastatin are derived from natural products and fluvastatin is 
totally synthetic recemic mixture (Illingworth and Tobert, 1994). 
Lovastatin, simvastatin and pravastatin are derived from fungi. 
Simvastatin is chemically modified 2,2-dimethyll butyrate analogue of lovastatin 
(Hoffman et al., 1986). Pravastatin is a purified active metabolite of mevastatin 
with an open hydroxyl acid instead of a lactone ring (Lennernas and Fager, 
1997). The fungal products lovastatin, pravastatin and simvastatin are 
structurally related since they have a hydronaphthalene in common and differ 
only at a few sites in the molecule (Figure 2.1).  
Furthermore, the major difference between the open form of the 
substituent R3 and HMG-CoA is the presence of methyl group on R3 (Figure 
2.1 and 2.2). The inhibitors with a lactone substituent R3 must tautomerise to 
the open form in vivo to become active. 
In addition, lovastatin and simvastatin are orally administered as inactive 
prodrugs in the lactone form, whereas pravastatin is given in the active open 
hydroxyl acid forms. Fluvastatin is purely synthetic and is given orally in its 
active hydroxyl acid form (Lennernas and Fager, 1997).   
 
2.2.2 Pharmacological Actions and Therapeutic Used 
The drugs which are able of lowering circulating blood lipid level was 
discovered in the early 1950s, before epidemiological studies showing a direct 
correlation between cholesterol blood levels and coronary risk (Kannel et al., 
1961 cited by Desager and Horsmans, 1996). However, before 1970, lipid 
lowering therapy was not considered satisfactory because of its adverse effects. 
Additionally, improvement in the knowledge of cholesterol biosynthesis and 
catabolism provide an opportunity for researchers to design and synthesize new 
drugs (Grundy, 1969 cited by Desager and Horsmans, 1996).  
Moreover, the second generation fibrates (e.g. fenofibrate), that act 
mainly by breaking down cholesterol (or cholesterol containing particles), 
opened a new era. At the same time, Endo (1992) began an intense period of 
research into therapeutic inhibition of cholesterol biosynthesis.  
The four 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors used today are lovastatin, simvastatin, pravastatin and fluvastatin 
(Desager and Horsmans, 1996). The HMG-CoA reductase is the key enzyme of 
cholesterol synthesis. HMG-CoA reductase inhibitors are potent reversible 
inhibitors of this enzyme, which act by competing for the substrate HMG-CoA 
(Desager and Horsmans, 1996). 
The statins are reversible inhibitors of the microsomal enzyme HMG-CoA 
to mevalonate. This is an early rate limiting step in cholesterol biosynthesis 
(Lennernas and Fager, 1997). The rate limiting enzyme in cholesterol synthesis 
is 3-hdroxy-3-methylglutaryl-coenzyme A reductase. This enzymatic activity 
takes place during the early steps that lead from acetate to cholesterol skeleton 
(Desager and Horsmans, 1996). Figure 2.2 shows the mevalonate pathway and 
cholesterol synthesis. Inhibition of HMG-CoA reductase by statins decreases 
intracellular cholesterol biosynthesis. The liver is the target organ for the statins, 
since it is the major site of cholesterol biosynthesis, lipoprotein production and 
LDL catabolism (Lennernas and Fager, 1997).  
The hypocholesterolemic effects of HMG-CoA reductase inhibitors are 
based on the ability of these drugs to partially inhibit hepatic HMG-CoA 
reductase, thereby causing a depletion of cellular pool of cholesterol, which, in 
turn, leads to an increase in the expression of high affinity receptors for low 
density lipoprotein (LDL) on hepatocyte membranes and concurrently, a 
reduction in the synthesis of very low density lipoprotein and LDL (Illingworth 
and Tobert, 1994). 
HMG-CoA reductase inhibitors are now widely used and account for the 
majority of prescriptions for lipid lowering drugs in many countries. HMG-CoA 
reductase inhibitors are the most effective agents developed to date for the 
treatment of patients with primary and secondary hypercholesterolaemia 
associated with increased levels of LDL cholesterol (Illingworth and Tobert, 
1994; Lennernas and Fager, 1997). 
Lovastatin, simvastatin, pravastatin and fluvastatin have similar 
pharmacodynamic properties. All can reduce LDL-cholesterol by 20 to 35%, a 
reduction which has been shown to achieve decreases of 30 to 35% in major 
cardiovascular outcomes. Simvastatin has this effect at doses of about half 
those of other 3 statins (Lennernas and Fager, 1997). 
Finally, statins can exert a direct antiatherosclerotic effect on the arterial 
wall, beyond their lipid lowering properties, which could translate into a more 
significant prevention of heart disease (Corsini et al., 1999).  
 
 Figure 2.1 Chemical structures of the main 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (Adopted 
from Desager and Horsmans, 1996)  
 
  
Figure 2.2 The mevalonate pathway and cholesterol synthesis 
(Adopted from Desager and Horsmans, 1996) 
 
 
 
2.2.3 Overview of Pharmacokinetics Properties of 3-Hydroxy-3-
Methylglutaryl-Coenzyme A Reductase Inhibitors  
The pharmacokinetics of HMG-CoA reductase inhibitors have been 
summarized in several reviews (Slater and MacDonald, 1988; Henwood and 
Heel, 1988; Pan et al., 1990; Todd and Goa, 1990; Pentikainen et al., 1992; 
Jungnickel et al., 1992; McTavish and Sorkin, 1992; Mauro, 1993; Quion and 
Jones, 1994; Illingworth and Tobert, 1994; Deslypere, 1995; Plosker and 
McTavish, 1995; Plosker and Wagstaff, 1996; Haria and McTavish, 1997; Lea 
and McTavish,1997; Kong et al., 1997; Paoletti et al., 2002).  
Six reviews have specifically focused on the similarities and differences 
of HMG-CoA reductase inhibitors (Desager and Horsmans, 1996; Lennernas 
and Fager, 1997; Christians et al., 1998; Corsini et al., 1999; Davidson and 
Toth, 2004; Shitara and Sugiyama, 2006), and others have been devoted to 
specific aspects, such as tissue distribution (Sirtori, 1993) and drug interactions 
(Christians et al., 1998; Jacobson, 2004; Shitara and Sugiyama, 2006). The 
pharmacokinetics of HMG-CoA reductase inhibitors are compared in Table 2.1.  
In general, statins absorption from the small and large intestine is 
affected by dose/dissolution ratio, dissolution rate, degradation/metabolism in 
the lumen, complex binding in the lumen, intestinal transit and effective 
permeability across the intestinal mucosa (Lennernas and Fager, 1997). 
Lovastatin and simvastatin are prodrugs and are converted by hydrolytic 
enzymes in the plasma and liver to the active acid form (Tang and Kalow, 
1995). All other HMG-CoA reductase inhibitors are given in their active form.  
Moreover, lovastatin and simvastatin in their lactone form, but not in their 
acid form, cross the blood brain barrier (Tsuji et al., 1993; Saheki et al., 1994; 
Lennernas and Fager, 1997). More hydrophilic HMG-CoA reductase inhibitors, 
such as pravastatin and fluvastatin do not reach the central nervous system 
(CNS) in measurable concentrations (Tsuji et al., 1993; Saheki et al., 1994; 
Christians et al., 1998). Distribution into the CNS is dependent on lipophilicity 
(Sirtori, 1993) and affinity to p-glycoproteins, which constitute an important 
efflux mechanism for lipophilic drugs as part of the blood-brain barrier (Tsuji et 
al., 1993; Saheki et al., 1994; Shitara and Sugiyama, 2006). In addition, 
immunosuppressants such as cyclosporine, tacrolimus, and sirolimus 
(Christians et al., 1996, Corsini et al., 1999) and several HMG-CoA reductase 
inhibitors are p-glycoprotein substrates. This constitutes a potential drug 
interaction locus which results in enhanced access of HMG-CoA reductase 
inhibitors and/or immunosuppressants into the CNS.  
Pravastatin is the only HMG-CoA reductase inhibitor that is mainly 
eliminated unchanged (Quion and Jones, 1994). Its main metabolite is inactive 
and it has a terminal plasma half-life slightly shorter than that of pravastatin 
(Corsini et al., 1999; Davidson and Toth, 2004; Shitara and Sugiyama, 2006). 
All other HMG-CoA reductase inhibitors are eliminated mostly as metabolites 
and with the exception of fluvastatin, have active metabolites that significantly 
contribute to their lipid-lowering effect. There is indirect evidence that active 
metabolites of lovastatin, simvastatin, atorvastatin and cerivastatin with longer 
terminal half-life than the parent compound exist, but none of these has been 
well characterized (Corsini et al., 1999).  
Pharmacokinetic studies using non-specific analytical methods yielded 
markedly longer terminal plasma half-life for lovastatin and simvastatin than 
studies using specific methods (Lennernas and Fager, 1997). Long terminal 
half-life of the parent drug or its metabolites was led to accumulation in plasma 
and tissues, which can facilitate toxic consequences. Since drug interactions 
with the elimination of HMG-CoA reductase inhibitors complicate lipid-lowering 
therapy in cyclosporine treated transplant patients, an HMG-CoA reductase 
inhibitor with short terminal half-life for parent drug and metabolites, such as 
pravastatin or fluvastatin, might be a safer choice in this specific group of 
patients. Among the HMG-CoA reductase inhibitors, pravastatin exhibits the 
highest clearance by the kidney. It is eliminated both by the kidneys (average, 
47%) and the liver (53.00%) to a similar extent (Singhvi et al., 1990; Quion and 
Jones, 1994). Pravastatin pharmacokinetics were not significantly changed in 
patients with mild, moderate, and severe kidney dysfunction in comparison with 
healthy controls (Halstenson et al., 1992), implying that impaired renal 
clearance was compensated for by an increase in liver clearance.  
The plasma concentrations of total HMG-CoA reductase inhibitors after a 
single dose of lovastatin were 2-fold higher in patients with renal insufficiency 
(creatinine clearance < 30 mL.min-1) (Christians et al., 1998; Corsini et al., 
1999; Davidson and Toth, 2004), as compared with patients with normal renal 
function, leading to the recommendation that lovastatin doses > 20 mg. day-1 
should be implemented with caution in these patients. The extent of dosage 
adjustment applies to transplant patients, for whom low lovastatin doses of < 20 
mg are recommended, but who are at a higher risk than non transplant patients 
due to drug interactions with cyclosporine, is unknown. There are no significant 
changes in the area under the curve (AUC) values of atorvastatin and 
cerivastatin (Christians et al., 1998) found in patients with renal impairment.  
Data about the influence of impaired kidney function on simvastatin and 
fluvastatin pharmacokinetics are not available. But since about 90% of these 
drugs are eliminated by the liver, little impact would be anticipated (Christians et 
al., 1998).  
Compared with healthy subjects, pravastatin AUC values were increased 
by only 34% in patients with liver cirrhosis (Christians et al., 1998, Davidson and 
Toth, 2004; Shitara and Sugiyama, 2006). Fluvastatin AUC and Cmax values 
were 2.5 fold higher in patients with liver cirrhosis than in healthy subjects. 
Atorvastatin AUC values and Cmax were 7 and 5 fold higher, respectively, in 
patients with impaired liver function than in healthy controls and the increase 
was dependent on the severity of liver disease: the AUC values were 4 fold 
higher in patients with Childs-Pugh A and 12 fold higher in patients with Childs-
Pugh B liver impairment. The elimination half-life and Tmax were not changed, 
but the higher AUC values did result in a more efficient lipid-lowering effect. On 
the basis of these pharmacokinetic changes, atorvastatin is not recommended 
for treatment of patients with liver dysfunction (Christians et al., 1998).  
Additionally, the effect of impaired liver function on the plasma 
concentrations of lovastatin, simvastatin (Christians et al., 1998), and 
cerivastatin has not been reported yet, but considering the important role of the 
liver in their elimination, a significant effect can be expected. In addition, in 
transplant patients with cholestasis, such as liver graft patients (Christians et al., 
1991) and bone marrow graft patients with graft versus host disease of the liver 
(Christians et al., 1996; Christians et al., 1998), cyclosporine metabolites 
accumulate and potentially enhance the cyclosporine drug interaction with the 
elimination of HMG-CoA reductase inhibitors. At the moment, pravastatin is the 
only HMG-CoA reductase inhibitor studied in liver graft patients, and it was 
found to be safe (Christians et al., 1998; Corsini et al., 1999; Davidson and 
Toth, 2004; Shitara and Sugiyama, 2006). 
Fresh or frozen grapefruit inhibits intestinal CYP3A4 but appears to have 
minimal effects on hepatic CYP3A4. Therefore, grapefruit juice (at least 200 
mL) can increase serum concentrations of numerous CYP3A4 substrate drugs 
that undergo intestinal first-pass metabolism by this enzyme. This effect has 
been reported by Kupferschmidt et al (1993); Hollander et al (1995); Ameer and 
Weintraub (1997); Lilja et al (1998); Gruer et al (1999).  
Grapefruit juice was reported to significantly increase serum 
concentrations of the calcium channel blocker felodipine and simvastatin. 
Pravastatin pharmacokinetics is not affected by grapefruit juice (Ameer and 
Weintraub, 1997; Lilja et al., 1999; Shitara and Sugiyama, 2006). The primary 
substance responsible for inhibition was identified in vitro to be a 
furanocoumarin compound which is widely found in nature, 6,7-
dihydroxybergamottin. This inhibitory substance is less potent than known 
CYP3A4 inhibitors such as ketoconazole, and itraconazole (Neuvonen et al., 
1997). There is a lack of published reports of myopathy caused by grapefruit 
juice and CYP3A4 statins are lacking. 
Nevertheless, it is probably advisable to separate by 2 hours the dosing 
of CYP3A4 statins with grapefruit juice (Lilja et al., 2000). Orange juice, which 
lacks 6,7-dihydroxybergamottin, does not inhibit CYP3A4. Little is known about 
the effects of other citrus fruits on CYP enzymes (Fuhr and Frummert 1995; 
Ameer and Weintraub, 1997). 
Table 2.1 Comparison of HMG-CoA Reductase inhibitors (Adopted from Christians et al., 1998) 
Parameter Lovastatin Simvastatin Pravastatin Fluvastatin Atorvastatin Cerivastatin 
Prodrug Yes Yes No No No No 
Crosses blood brain barrier Lactone Lactone No No N.A N.A. 
Lipophilicity Lipophilic Lipophilic Hydrophilic Hydrophilic Lipophilic N.A. 
Oral pharmacokinetics 
• Dose (mg/day) 
• Absorption (%) 
• Bioavailability (%) 
• Effect of food  
      
20-8 10-40 20-4 20-80 2.5-80 0.1-0.3 
30 60-85 35 98 N.A. N.A. 
< 5 < 5 10 10-35 12 60 
↑ 50% No ↓ 30% ↓ 15-25% ↓ 13% ↓23% 
Tmax                                        2-6 1.3-2.4 0.9-1.6 0.5-1.5 2-4 0.5-4 
Terminal half-life (hr) 2.5-15 1.9-15.6 1.3-2.6 0.5-3.1 14 1.7-2.7 
Hepatic extraction (%) 62-69 >78 46 68 N.A. N.A. 
Renal elimination (%) 30 13 20-60 6 < 2 30 
Protein binding (%) > 90 > 90 43-48 95-98 > 95 N.A. 
p-Glycoprotein substrate Yes N.A. Yes Yes N.A. N.A. 
CYP substrate CYP3A CYP3A No CYP2C9 CYP3A CYP3A 
Metabolites effect Yes Yes No No Yes Yes 
Mostly eliminated as Metabolites Metabolites Unchanged Metabolites N.A. Metabolites 
              N.A., not available 
2.3 Simvastatin 
2.3.1 Chemical Structure  
Simvastatin is a methyl analogue of lovastatin and is synthesized from a 
fermentation product of Aspergillus terreus (Hoffman et al., 1986). Simvastatin 
is a nonhygroscopic white crystalline powder, insoluble in water but quite 
soluble in chloroform, methanol and alcohol (Mauro, 1993) with pKa of 4.68 
(Corsini et al., 1999). The molecular weight of this compound C25H38O5 is 
418.57. Simvastatin is the pharmacologically inactive lactone form of 
simvastatin acid, butanoic acid, 2,2-dimethyl-1,2,3,7,8,8a-hexahydro-3,7-
dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl) ethyl]-1-naphthalenyl 
ester. Simvastatin is a lactone which needs the opening of the ring for it to 
become active. Figure 2.3 shows the chemical structure of simvastatin (Mauro, 
1993). 
